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Abstract 
The use of somatostatin analogs is a new conservative therapeutic approach for the 
treatment of chyle fistulas developing after thyroid cancer surgery. The combination 
therapy with a total parenteral nutrition should avoid the high morbidity of a 
re-intervention with an uncertain outcome. This promising trend is supported by the 
present case report of a chyle leak occurring after total thyroidectomy with central and 
lateral neck dissection for a papillary carcinoma, which was treated successfully without 
immediate or distant sequelae. 
 
Introduction 
Thoracic duct injury is a rare but troublesome complication of cervical surgeries. First 
described by Cushing in 1898, chyle fistula can induce severe nutritional, metabolic and 
immune disturbances, delay wound healing, prolong hospital stay and, in the past, even 
resulted in death [1, 2]. The incidence rate reported in the literature ranges from 0.5 to 
2.5% [1–8]. In thyroid surgery, the rate of chyle fistula increases significantly (p < 0.001) 
with the extent of the surgical procedure: 0.5% after less than total surgery with central 
compartment node dissection (CCND), 0.8% in patients with total thyroidectomy and 
CCND, 5.1% after total thyroidectomy associated with ipsilateral neck dissection, and 
6.2% in patients treated by total thyroidectomy with bilateral neck dissection [5]. Due to 
anatomic reasons (left side termination of thoracic duct in 75–92%), these injuries occur 
predominantly on the left side in patients undergoing lateral neck dissection [3, 5, 9]. 
Conversely, Roh et al. [9] reported a higher but not significant incidence of chyle leakage Case Rep Oncol 2011;4:255–259 
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on the right side (8.9 vs. 7.5%; p = 0.802). Most chyle fistulas (25–75%) develop 
postoperatively, with a 86% rate of occurrence between the first and the third 
postoperative day [6]. 
Case Report 
A 27-year-old woman was referred to our department for the surgical treatment of a goiter with 
hyperthyroidism treated for 2 years with neomercazole 10 mg/day and levothyrox 50 μg/day. Physical 
examination revealed an enlarged thyroid associated with left mid-lower jugular nodes. 
Ultrasonography showed a suspicious 11-mm nodule in the left superior lobe and two ipsilateral 20-mm 
cervical nodes. Fine needle cytology aspiration of cervical lymphadenopathy confirmed the involvement 
of a papillary thyroid cancer. In May 2010, a total thyroidectomy with central and left lateral neck 
dissection was performed. 
Pathologic specimen examination showed a 12 × 15 mm papillary cancer in the left superior lobe 
without extrathyroid extension. Three out of the 42 nodes removed were metastatic. 
On the third postoperative day, a high-output lymph fistula with milky appearance was observed 
following a drainage collection of 2,300 ml. We decided to adopt a conservative medical management 
consisting of a diet of medium-chain triglycerides for 3 days. Persistence of the fistula (1,400 ml/day) on 
day 6 led to the introduction of a strict diet and parenteral nutrition, followed by a 50% reduction of the 
daily drainage (700 ml/day) of the chyle fistula. On day 8, after adjunction of a pharmacological 
treatment with subcutaneous octreotide (0.1 mg every 8 h), the fistulous debit decreased gradually until 
it disappeared completely after 6 days (fig. 1). No side effects were observed. Oral nutrition was initiated 
and the cervical closed suction drains removed. On postoperative day 16, the patient was discharged 
home in good condition with correct wound healing. 
One month later, the patient underwent a radioablation therapy (3.56 GBq) after a radioiodine 
scanning revealed no persistent disease or distant metastases. After a follow-up of 10 months, this young 
female had no signs of either local and/or distant recurrence or of postoperative functional and cosmetic 
sequelae. 
Discussion 
Priority must be given to the prevention of lymph fistulas related to an injury of the 
main thoracic duct or one of its multiple branches (40% of cases) [3, 6, 8, 10]. A 
meticulous surgical technique combined with magnifying glasses has recently been 
advocated by Lorenz et al. [6]. Intraoperative diagnosis of lymphatic leakage is better 
treated immediately by ligature (3-0 or 4-0 non-absorbable) than suture procedures [6, 9]. 
In most cases, postoperative diagnosis is clinically obvious and no complementary 
investigations such as lymphoscintigraphy and/or CT scan are required [3, 8]. Chyle 
fistula usually starts after an oral diet, with an increase of drainage volume with milky 
appearance, swelling of supraclavicular fossa, erythema or induration of the skin [3, 6, 8]. 
Measurement of triglyceride concentrations in postoperative fluid drainage may assist the 
early diagnosis of chyle fistula. A triglyceride level exceeding 100 mg/dl, a greater serum 
concentration or a lymphocyte count of 50% are thought to support the diagnosis [4, 
6–9, 11]. 
Although several therapeutic approaches, including nutritional, surgical and 
pharmacological procedures, have been proposed, there is currently no clear consensus 
on the optimal management of thoracic duct fistulas [5]. The decision between Case Rep Oncol 2011;4:255–259 
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conservative and surgical treatment options still remains a subject of debate in literature 
reviews [5–8, 11]. 
Conservative medical management includes several lines of treatment and is 
imperatively associated with adequate drainage, applying pressure dressing, serial 
aspirations, bed rest and nutritional modifications [1, 6–8, 12]. Except for initially large 
chyle leaks, conservative methods should be considered first since they allow a cure rate 
ranging from 58 to 100% [6]. 
The first step is an elemental diet supplemented with medium-chain triglycerides, 
directly absorbed into the portal circulation by passing the lymphatic system [4, 6–9]. 
Conversely, long-chain triglycerides entering the blood stream via the chyle should be 
avoided [4, 7, 8]. According to Lorenz et al. [6], dietary restriction was less successful than 
total fasting. 
In case of failure and despite the increased costs, a total parenteral nutrition is 
recommended as a second-line approach in most institutions [4, 6–8]. Conservative 
medical treatment should not exceed 30 days. Furthermore, the optimal timing and the 
decision between conservative and surgical options remain unclear. For Coşkun et al. [7] 
and others [1, 4, 8, 9], a persistent drainage output of >600 ml/day for 5–7 days despite 
medical conservative therapy or an extremely high output (>1.5–2 liters) may require 
surgical re-intervention. More recently, Lorenz et al. [6] have suggested a daily 300-ml 
output drainage threshold and an early decision on day 4 after initiating fasting protocol 
in favor of either continued medical treatment or surgery. 
The aim of surgical therapy is to close the leak site with local application of fibrin glue, 
a pectoralis major muscle flap transfer or an absorbable mesh [6–9]. En bloc ligature of 
the thoracic duct by videothoracoscopy has also been proposed in patients who not 
respond to cervical re-intervention [2, 3, 5, 9, 11]. However, sclerotherapy devices with 
topical application of tetracycline or doxycycline have been abandoned because of local 
neurotoxicities (phrenic or vagus nerve palsy) [2, 6, 9]. 
Somatostatin and its long-acting analog octreotide were first described in 1990 by 
Ulíbarri et al. [13] as an effective and successful adjunct to conservative therapy of 
iatrogenic thoracic duct injuries. These preliminary data were confirmed 10 years later by 
Markham et al. [14] in a prospective study on dogs demonstrating a threefold decrease in 
thoracic duct fistula output after administration of octreotide. The exact mechanism of 
action of this neurohormonal and panacrine agent remains unknown. It reduces 
gastrointestinal chyle production by decreasing splanchnic blood flow and decreasing 
gastric, biliary, pancreatic and intestinal secretions [1, 2, 4, 7, 11]. Administered at a 
recommended dose of 3.5–12 μg/kg/h for 3–14 days [11], octreotide therapy requires 
good monitoring of blood glucose levels every 6 h because of the inhibition induced by 
insulin, glucagon and motilin secretion [2]. The risk of cholecystitis secondary to 
cholestasis should also not be underestimated in patients eligible for prolonged treatment 
[1]. In addition to recent data [1, 4, 6–8, 11, 15], our observation demonstrated that 
octreotide is a promising alternative therapy useful for decreasing chyle fistula after 
thyroid cancer surgery and increasing the success of conservative management of this 
worrying complication. Case Rep Oncol 2011;4:255–259 
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Advances in surgeons’ knowledge of the anatomic landmarks and variability of the 
cervical portion of the thoracic duct should minimize the incidence of injuries which lead 
to an often unrecognized but significant morbidity rate [10]. 
 
 
Fig. 1. Evolution of the chyle fistula leak. MCT = Middle-chain triglyceride; SC Octreotide = 
subcutaneous octreotide administration; TPN = total parenteral nutrition. 
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